Table 1 Distribution of mutated sites by gene and by TIER classification
From: Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type
TIER1 | TIER2 | TIER3 | PASSENGER | |||||
|---|---|---|---|---|---|---|---|---|
Gene | N | % | N | % | N | % | N | % |
PIK3CA | 8 | 29.6% | 15 | 9.1% | 117 | 9.5% | 126 | 7.1% |
FBXW7 | 6 | 22.2% | 8 | 4.8% | 117 | 9.5% | 100 | 5.7% |
KRAS | 5 | 18.5% | 7 | 4.2% | 31 | 2.5% | 35 | 2.0% |
PTEN | 2 | 7.4% | 23 | 13.9% | 63 | 5.1% | 69 | 3.9% |
ERBB3 | 2 | 7.4% | 1 | 0.6% | 82 | 6.6% | 141 | 8.0% |
TP53 | 1 | 3.7% | 69 | 41.8% | 123 | 10.0% | 108 | 6.1% |
ERBB2 | 1 | 3.7% | 5 | 3.0% | 81 | 6.6% | 121 | 6.9% |
EP300 | 1 | 3.7% | 3 | 1.8% | 199 | 16.1% | 211 | 12.0% |
MAPK1 | 1 | 3.7% | 0 | 0.0% | 13 | 1.1% | 20 | 1.1% |
ARID1A | 0 | 0.0% | 11 | 6.7% | 112 | 9.1% | 344 | 19.5% |
STK11 | 0 | 0.0% | 11 | 6.7% | 35 | 2.8% | 47 | 2.7% |
NFE2L2 | 0 | 0.0% | 5 | 3.0% | 21 | 1.7% | 59 | 3.3% |
PIK3R1 | 0 | 0.0% | 4 | 2.4% | 64 | 5.2% | 55 | 3.1% |
HRAS | 0 | 0.0% | 3 | 1.8% | 24 | 1.9% | 35 | 2.0% |
TGFBR2 | 0 | 0.0% | 0 | 0.0% | 76 | 6.1% | 49 | 2.8% |
CASP8 | 0 | 0.0% | 0 | 0.0% | 51 | 4.1% | 61 | 3.5% |
ELF1 | 0 | 0.0% | 0 | 0.0% | 16 | 1.3% | 35 | 2.0% |
HLA-B | 0 | 0.0% | 0 | 0.0% | 10 | 0.8% | 11 | 0.6% |
HLA-A | 0 | 0.0% | 0 | 0.0% | 1 | 0.1% | 5 | 0.3% |
MED1 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 132 | 7.5% |
Total | 27 | 100.0% | 165 | 100.0% | 1236 | 100.0% | 1764 | 100.0% |
